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Stem cell research has opened new ex-
perimental avenues for researching the
mechanisms of debilitating diseases. More-
over, due to their ability to differentiate into
highly specific cells with various functions,
stem cells can provide a renewable source
of replacement cells or tissue to treat dis-
ease. Because of their immense promise,
pharmaceutical companies are rapidly initi-
ating the development of stem-cell based
therapeutics with the goal of revolutioniz-
ing disease treatment.
Stem cell technologies have begun to
transform areas of drug discovery for phar-
maceutical companies. Currently, these
cells are used in high throughput screens
(HTS†), which use extensive automation to
test hundreds of thousands of compounds
targeted toward the treatment of particular
diseases. In such screens, stem cells would,
ideally, provide limitless numbers of
human cells for testing different character-
istics of new therapeutics, including drug
pharmacology, toxicology, and cytotoxicity
[1].
During a panel entitled Translation to
Clinic at the StemCONN 2009 conference
in New Haven, Connecticut, in March,
John D. McNeish, Ph.D., discussed the use
of HTS at Pfizer Inc. in the last decade.
Pfizer screens compounds with animal and
adult stem cells to identify safer drugs.
Pfizer also uses HTS to find drugs that may
prompt the body to regenerate pancreas
cells destroyed by the immune system in
diabetes patients [2].
Although the use of embryonic stem
(ES) cells has been quite controversial, the
impact of ES cells on drug development is
promising. ES cells can differentiate into
any cell type and be directed to become dis-
eased cells [3].These newly generated cells
then may be used as an advanced platform
for testing pharmaceutical compounds in
vitro. The use of stem cells in HTS is just
one application for stem cells in healthcare
and represents a novel technology in drug
development.
Recent academic stem cell research
has provided some groundwork for the de-
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Administration.velopment of future drug therapies. Haifan
Lin, a leading stem cell researcher at Yale
University, spoke at the conference about
cancer stem cells. Like stem cells in general,
cancer stem cells self renew and differenti-
ate, although they form tumors as a result of
this process [4]. In vivo, stem cells and can-
cer stem cells are found in an extremely
complex environment or niche. The cells
within the niche, or “niche cells,” transmit
signals that control stem cell regulation and
differentiation.The tumor cell niche, in par-
ticular, can reprogram surrounding stem
cells, causing them to become diseased or
tumorgenic by switching on or off particular
genes [5]. Current drug therapies target tu-
mors by killing cancer cells without affect-
ing cancer stem cells [4]. To target the
cancerous stem cells, researchers must first
understand the signals, proteins, and prop-
erties of the environment involved in stem
cell regulation. The generation of drugs tar-
geting these mechanisms could treat cancer
more specifically than current methods
allow.
The applications of stem cell research
are not limited to cancer treatment. Stem
cells are already important participants in
more than 182 clinical trials worldwide. Re-
cently, Geron received U.S. Food and Drug
Administration (FDA) approval to begin the
world’s first human clinical trial of an em-
bryonic stem cell-based therapy used for the
regeneration of myelin, the protective cover
of nerve cells [6]. Geron’s product,
GRNOPC1, has been shown to help re-
myelination and nerve growth in animal
models [7], and the ultimate goal is to
achieve the restoration of spinal cord func-
tion in patients with spinal injuries. Also, a
British company, ReNeuron, received ap-
proval to start clinical trials with gene-mod-
ified neural stem cells for the treatment of
stroke [8].
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